Patel Sushil sold $1.0M of RVMD
Patel Sushil sold 5,580 shares of Revolution Medicines, Inc. (RVMD) at an average of $187.99 ($183.17–$192.61, $1.05M total) across 9 trades on 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider’s post-transaction holdings (21,656 shares) and confirms the sale was pre-arranged under Rule 10b5-1.
Market read
Provides a fresh, auditable datapoint on insider selling size and timing, but without any fundamental company catalyst.
What to watch
Traders may still watch for follow-on insider activity (additional sales/buys) and whether other disclosures (clinical/regulatory) coincide with the same period.
Background
The article is an SEC Form 4 insider transaction: director Patel Sushil sold RVMD shares in multiple trades on 2026-06-29.
Ticker impact
Revolution Medicines director Patel Sushil sold about $1.05M of RVMD shares via an open-market sale under a 10b5-1 plan on 2026-06-29.
Likely limited near-term impact; any effect is more about sentiment/positioning than fundamentals.
The filing provides exact sale size, dates, and weighted-average price, but no accompanying fundamental catalyst (earnings, trial, deal, or guidance).
Market effects
Minimal; this is company-specific insider transaction disclosure with no sector-wide regulatory/clinical signal.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than negative expectations, so the market may discount it.
Key entities
- issuerRevolution Medicines, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderPatel Sushil
Director who executed the open-market sale under a 10b5-1 plan.
